Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Analysis of the Recent HTA Decision Making Landscape for Multiple Sclerosis Therapies - Trends and Future Opportunities.
Risk of Relapse Among Propensity Score Matched Multiple Sclerosis Patients Receiving Natalizumab or Platform Therapy in the US.
Budget Impact Analysis of Fingolimod in Relapsing Remitting Multiple Sclerosis.
BIIB033 single ascending dose study in healthy volunteer subjects
Histologie de la sclerose en plaques
Cortical functional modifications following optic neuritis.
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells.
Does Current Portuguese Financing Model for Multiple Sclerosis Covers for Estimated Needs?
Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis.
Optic neuritis as a presenting symptom of Mycoplasma pneumoniae infection.
Astrocytic IL-6 Influences the Clinical Symptoms of EAE in Mice.
Working Ability and Monetarily Valued Productivity of Patients with Multiple Sclerosis Treated with Natalizumab.
The association of IL-18 gene promoter polymorphisms and the levels of serum IL-18 on the risk of multiple sclerosis.
Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement
Development of a central nervous system axonal myelination assay for high throughput screening.
The effectiveness of a self-management occupational therapy intervention on activity performance in individuals with multiple sclerosis-related fatigue: a randomized-controlled trial.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Construct Validity of the Four Square Step Test in Multiple Sclerosis.
Analysis of Expenditure in Multiple Sclerosis Disease Modifying Therapies Evolution Between 2004-2013 in Spain.
Boosting CNS axon regeneration by circumventing limitations of natural cytokine signaling.
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
Information processing speed in multiple sclerosis: Past, present, and future.
All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.